MDPI

Review

Recent Advances in the Synthesis and Applications of m-Aryloxy Phenols

Dinara Amankulova [1] , Gulzat Berganayeva [1], Bates Kudaibergenova [1], Dinara Zhetpisbay [2], Ayshagul Sharipova [3] and Moldyr Dyusebaeva [1,*]

[1] Faculty of Chemistry and Chemical Technology, Al-Farabi Kazakh National University, 71 al-Farabi Ave., 050042 Almaty, Kazakhstan

[2] Department of Biochemistry, Asfendiyarov Kazakh National Medical University, 94 Tole bi Ave., 050012 Almaty, Kazakhstan

[3] Chemical and Technological Faculty, Karakalpak Berdah State University, 1 Ch. Abdirov St., Nukus 230100, Uzbekistan

* Correspondence: moldyr.dyusebaeva@mail.ru

Abstract: Since phenol derivatives have high potential as building blocks for the synthesis of bioactive natural products and conducting polymers, many synthesis methods have been invented. In recent years, innovative synthetic methods have been developed for the preparation of m-aryloxy phenols, which has allowed for the preparation of complex m-aryloxy phenols with functional groups, such as esters, nitriles, and halogens, that impart specific properties of these compounds. This review provides an overview of recent advances in synthetic strategies for m-aryloxy phenols and their potential biological activities. This paper highlights the importance of m-aryloxy phenols in various industries, including plastics, adhesives, and coatings, and it discusses their applications as antioxidants, ultraviolet absorbers, and flame retardants.

Keywords: m-aryloxy phenols; potential biological activities; hydroxylation of benzenes; nucleophilic aromatic substitutions; electrophilic aromatic substitutions; metal-catalyzed cross-coupling reaction

1. Introduction

m-Aryloxy phenols have a wide range of applications, including as antioxidants, ultraviolet absorbers, and flame retardants. They are commonly used in the production of plastics, adhesives, and coatings due to their ability to improve these materials' thermal stability and flame resistance. In addition, m-aryloxy phenols have been found to have potential biological activities, including anti-tumor and anti-inflammatory effects [1].

Phenol derivatives have been widely researched, as they have high potential for synthesizing bioactive natural products and conducting polymers. Many synthesis methods have been developed for phenol derivatives, with conventional strategies focusing on functionalizing and transforming functional groups around the aromatic ring. These strategies include selective hydroxylation of benzenes, nucleophilic and electrophilic aromatic substitutions, and metal-catalyzed cross-coupling reactions [2].

The most successful synthesis strategies were developed based on the Ullmann copper-mediated aromatic nucleophilic substitution reactions, which were reported in the early 1900s by Fritz Ullmann and Irma Goldberg. In the original Ullmann reaction protocol, stoichiometric amounts of copper salt were used, along with high reaction temperatures (≥200 °C) and prolonged reaction times. However, the modern variants of the Ullmann reaction have focused on using copper-mediated (stoichiometric or catalytic) reactions between aryl halides and other reagents, such as amines, phenols, or thiophenols, to produce aryl-amine, -ether, or -thioether compounds, respectively (Scheme 1) [3,4].

Scheme 1. Schematic representation of the Ullmann reaction and Ullmann condensation.

Despite the expanded scope of the Ullmann reaction, the term primarily refers to the copper-catalyzed synthesis of biaryls from aryl halides. This protocol has been widely adopted due to its high efficiency and versatility in constructing complex biaryl compounds. The Ullmann reaction remains an essential tool in modern organic synthesis and has contributed significantly to the development of many natural products, pharmaceuticals, and materials [5].

Although nucleophilic aromatic substitution is a highly effective method for synthesizing phenol derivatives, the strong influence of the hydroxyl group on ortho/para substitution makes it difficult to prepare meta-substituted phenol derivatives.

The synthesis of m-aryloxy phenols is a significant area of research, as it allows for the preparation of new compounds with tailored properties and applications. In light of their unique properties and broad range of applications, m-aryloxy phenols represent an important area of research with significant potential for future developments. This paper reviews the recent advances in the synthesis of m-aryloxy phenols, as well as their applications in various industries, and highlights the potential for further research in this field.

## 2. Synthesis of m-Aryloxy Phenols by Demethylation of m-Methoxy Phenols

The demethylation reaction involves the elimination of a methyl group from a molecule. One example of this reaction is the demethylation of m-methoxy phenols, which forms m-aryloxy phenols.

There exist multiple approaches for demethylation, including chemical and catalytic methods. The most prevalent chemical method involves the utilization of potent acids, such as sulfuric acid, hydrochloric acid, or nitric acid. These acids convert the methoxy group into a hydroxyl group [6].

In contrast, catalytic demethylation methods usually use transition metal catalysts, including copper or palladium. These methods can be employed through various mechanisms, including hydrogenation, transfer hydrogenation, and activation of C-H bonds.

The use of hydrogen bromide and boron tribromide (BBr_3) as catalysts in demethylation reactions represents a valuable approach for the synthesis of m-aryloxy phenols. Bronsted acid HBr and Lewis acid BBr_3 can coordinate with electron-rich sites in organic compounds and enhance the outcome of organic reactions. This property enables the efficient demethylation of methoxy phenols to m-aryloxy phenols [7,8].

In Kormos and his team's research, 4-(3-hydroxyphenoxy) benzoic acid was synthesized from 4-(3-methoxyphenoxy) benzoic acid by refluxing it with 48% hydrogen bromide in acetic acid. By condensing the 4-(3-hydroxyphenoxy) benzoic acid with piperazine using N-ethylcarbodiimide hydrochloride (EDC·HCl) and a catalytic hydroxy benzotriazole (HOBt), the team synthesized N-(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3-methylpiperazin-1-yl]-methyl}-2-methylpropyl-4-(3-hydroxyphenoxy) benzamide (Scheme 2) [9].

Scheme 2. Synthesis of 4-(3-hydroxyphenoxy) benzoic acid and its derivative with piperazine amine.

This compound showed strong antagonistic properties at the κ opioid receptor, with inhibition agonist-stimulated [35S]GTPγS binding in cloned human μ (DAMGO) -Ke(nM)a = 69 ± 14, δ (DPDPE) − Ke(nM)a = 625 ± 120, and κ (U69,593) − Ke(nM)a = 1.85 ± 0.51. The authors believed these compounds will be useful in the development of clinical candidates for treating conditions such as depression, anxiety, schizophrenia, and addictions, as well as serving as pharmacological tools [9–11].

In 2022, Yamamoto et al. reported the synthesis of N-(2-(3-hydroxyphenoxy)-4-nitrophenyl)methanesulfonamide through the demethylation of the corresponding methoxy derivatives by utilizing BBr3 as a dealkylating agent (Scheme 3). The resulting compound was utilized to synthesize isomeric [11C] methoxy analogs of nimesulide as a suitable radiotracer candidate for imaging the expression of Cyclooxygenase-2 (COX-2) in the brain. COX-2 expression has been documented in various tumor types, including head and neck cancers, colorectal cancers, and melanomas [12,13].

**Scheme 3.** Synthesis of N-(2-(3-hydroxyphenoxy)-4-nitrophenyl)methanesulfonamide.

In 2009, Yang [14] obtained 3,3′-oxydiphenol from the interaction of 3-methoxyphenol with 3-bromanisole in the presence of a Cu-catalyst and subsequent cleavage of methyl groups with HBr in acetic acid. In [15], 3,3′-oxidiphenol was used as a diaryl building block to produce various oxacalix[*n*]arenes with an odd number of aromatic units (*n* = 5, 7) in high yields. Calixarenes have hydrophobic cavities that can hold smaller molecules or ions, and they belong to a class of cavitands known in host–guest chemistry. Thanks to selective sorption, calixarenes have been widely used in practice, for example, as receptors for selective or group extraction of ions of various metals [16–18], catalysts, and enzymes [19–21].

3. Synthesis of Aryloxy Phenols by Reactions between Aryl Halides and Resorcinol

The reaction between aryl halides and resorcinol involves a nucleophilic aromatic substitution mechanism. In this mechanism, the resorcinol undergoes deprotonation under basic conditions and, subsequently, acts as a nucleophile on the aromatic ring of the aryl halide. This results in the formation of an intermediate species, in which the nucleophile

attacks the ring, leading to the substitution of the halide group. The intermediate species contains an oxide anion, which is formed due to the loss of a proton. The final product of the reaction is an aryloxy phenol, which can be obtained in a good quantity under appropriate reaction conditions [22].

In 2010, Vagin and colleagues published a study detailing the synthesis of 5-(3-hydroxyphenoxy)-2-nitroaniline from 5-chloro-2-nitroaniline and resorcinol. The reaction was performed using sodium hydride as a base and DMF as a solvent and was carried out under an argon atmosphere by heating the reaction mixture at 125 °C for 24 h. They then used a hydrogenation reaction with a Pd/C catalyst to obtain 4-(3-hydroxyphenoxy)-1,2-benzyldiamine (Scheme 4) [23].

Scheme 4. Hydrogenation reaction of 3-(3-amino-4-nitrophenoxy) phenol.

The resulting compound was employed in the development of a reliable and versatile method for creating dinuclear salphen systems [24]. The use of corresponding Cr (III) complexes demonstrated increased activity in significant reactions, such as the polymerization of γ-butyrolactone and the copolymerization of CO_2 with propylene oxide, highlighting the importance of bimetallic processes [23].

In 2015, Wang and his team prepared a self-promoted hydroxy-containing phthalonitrile system, comprised of 1,3-bis(3,4-dicyanophenoxy) benzene (BDB) and 4-(3-hydroxyphenoxy) phthalonitrile (HPPH) through an in situ reaction in a one-pot nucleophilic displacement reaction. This reaction involved the removal of a nitro-substituent from 4-nitrophthalonitrile (Scheme 5) [25].

Scheme 5. Synthesis of 4-(3-hydroxyphenoxy) phthalonitrile and 1,3-bis(3,4-dicyanophenoxy) benzene.

The resulting HPBD material was found to possess desirable processability and mechanical properties, including a high modulus, a high glass transition temperature, and excellent thermal stability. The polymerization of HPBD resulted in the formation of a phthalocyanine ring, an isoindole ring, and a triazine ring. Additionally, post-curing at high temperatures was observed to improve thermal stability and produce void-free resin structures, making HPBD suitable for use in industries such as aerospace and microelectronics [25,26].

In 2011, Bollini et al. published a synthesis of 4-(3-hydroxyphenoxy)-3-((tetrahydro-2H-pyran-2-yl)oxy) benzonitrile and 4-(3-hydroxyphenoxy)-3-benzyloxybenzonitrile from 4-fluoro-3-hydroxybenzonitrile through a two-step process (Scheme 6) [27].

Scheme 6. Synthesis of aryloxy phenols based on 4-fluoro-3-aryloxy benzonitrile and resorcinol.

The resulting compounds served as intermediates in the investigation of novel non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV [28]. The final compound, possessing a methoxy–ethoxy substituent, was obtained in four steps from 4-(3-hydroxyphenoxy)-3-((tetrahydro-2H-pyran-2-yl)oxy) benzonitrile and demonstrated significant activity, with an inhibitory concentration of 0.54 μM [27,29,30].

In 2011, Xia and colleagues developed a novel class of benzoxaborole β-lactamase inhibitors through a three-step synthesis process. First, they carried out a nucleophilic substitution of 2-bromo-4-fluorobenzaldehyde with resorcinol to obtain an ether. Then they used palladium-mediated boronylation on the ether to produce an aldehyde, which was finally reduced with NaBH₄ and underwent acid-catalyzed cyclization to create the final product—3-hydroxyphenoxybenzoxaborole (Scheme 7) [31,32].

**Scheme 7.** Synthesis of the 3-hydroxyphenoxybenzoxaborole.

The 3-hydroxyphenoxybenzoxaborole was found to be 2–3 times more potent than benzoxaborole in inhibiting CTX-M-9a [31].

In 2016, Kobayashi and his team synthesized 5-chloro-4-[4-chloro-2-fluoro-5-(3-hydroxyphenoxy-phenyl]-1,2-tetramethylene-4pyrazolin-3-one from 2,5-difluoro-4-bromonitrobenzene in seven steps, using the nucleophilic aromatic substitution reaction between 2,5-difluoro-4-bromonitrobenzene and 3-methoxy phenol to obtain an ether. The elimination of a methyl group using boron tribromide as a demethylation agent in the final step produced 5-chloro-4-[4-chloro-2-fluoro-5-(3-hydroxyphenoxy)-phenyl]-1,2-tetramethylene-4-pyrazolin-3-one (Scheme 8) [33].

The resulting compound showed promising results as an herbicide, with a good control effect on weeds, good sustainability, and selective action between crops and weeds. It can be used effectively as an ingredient in herbicides [33,34].

In 2018, Kazuia et al. successfully synthesized 3-(4-aminophenoxy)-phenol from p-fluoronitrobenzene and resorcinol (Scheme 9). The reaction was conducted using sodium hydroxide and DMSO at 50 °C for three hours. The final product was obtained after hydrogenation using a Pd/C catalyst in methanol and a hydrogen atmosphere for two hours [35].

The resulting compound was used to create a series of (benzoylaminophenoxy)-phenol derivatives that showed promising activity as anti-prostate cancer agents [35–37].

Scheme 8. Synthesis of a polycyclic pyrazolinone derivative containing an aryloxy phenol fragment.

Scheme 9. Synthesis of 4-(3-hydroxyphenoxy) benzamine.

In 2018, Frączk and his team published a synthesis of 2-(3-hydroxyphenoxy)-5-chlorobenzonitrile in two steps. The process involved a reaction of 3-fluoro-5-chlorobenzonitrile with 3-methoxyphenol in NMP and potassium carbonate in the first step, followed by demethylation using BBr$_3$ in DCM in the second step (Scheme 10) [38].


Scheme 10. Synthesis of 2-(3-hydroxyphenoxy)-5-chlorobenzonitrile.

The compound resulting from the synthesis by Frączk and his group in 2018 was an intermediate in creating novel diaryl ethers, which are NNRTIs with improved solubility. These inhibitors showed promising results with IC$_{50}$ values at low micromolar to sub-micromolar concentrations [38–40].

In 2022, a group led by Zhong published a synthesis method for producing 3-[2-chloro-4-(trifluoromethyl)phenoxy]phenol. The synthesis was accomplished through the displacement of 2-chloro-1-fluoro-4-(trifluoromethyl)benzene with resorcinol and required a high temperature (130 °C) and an inert atmosphere for a 24-h reaction time (Scheme 11) [41].

3-[2-chloro-4-(trifluoromethyl)phenoxy]phenol is an intermediate in the synthesis of MK-2305, a highly potent agonist for the G-protein-coupled receptor 40 [41,42].

Scheme 11. Synthesis of 3-[2-chloro-4-(trifluoromethyl)phenoxy]phenol.

The utilization of a catalyst in the nucleophilic aromatic substitution reaction between an aryl halide and resorcinol has been widely investigated. The selection of a suitable catalyst is contingent upon the reaction conditions and the desired outcome. Transition metal catalysts, including palladium and copper, have been demonstrated to be effective in catalyzing this reaction, potentially leading to an enhancement in reaction rate and/or improved regioselectivity. However, the implementation of a catalyst may also introduce practical drawbacks, such as an increased cost and the requirement for specific handling and disposal procedures. Copper chloride (CuCl) has been proven to be an effective catalyst in the reaction between an aryl halide and resorcinol, resulting in an improvement in reaction rate and/or regioselectivity [43–46].

In 2010, Xue and colleagues synthesized m-aryloxy phenols through a two-step procedure. First, they performed Ullmann couplings of m-methoxy phenol with iodobenzene derivatives using Cs_2CO_3 and a small amount of CuBr as a catalyst to produce the intermediate compound. Then they cleaved the methyl ethers using BBr_3, resulting in m-aryloxy phenols with high yields. These m-aryloxy phenols were then used to synthesize a new series of inhibitors of nNOSs, which were evaluated for their ability to inhibit three different NOS isozymes: rat nNOSs, bovine eNOSs, and murine iNOSs (Scheme 12) [47,48].

Scheme 12. Synthesis of m-methoxy phenols with iodobenzene derivatives using Cs_2CO_3 and a small amount of CuBr as a catalyst.

In 2010, Sapkota and colleagues published a study on a two-step copper catalyst-based synthesis of eight meta-aryloxy phenols from methoxy phenols and 2-bromonitrobenzene or 2,4-dibromo nitrobenzene. The yields of the final compounds varied between 7 and 58% (Scheme 13) [49].

The synthesized compounds were evaluated for their anti-oxidative properties by measuring their ability to reduce the DPPH free radical to DPPH-H. However, the majority of the compounds were inactive in this regard, with only a few compounds possessing a resorcinol structure exhibiting moderate antioxidant activity, although it was lower than that of ascorbic acid [49,50].

Scheme 13. Two-stage synthesis of new meta-aryloxy phenols based on a copper catalyst.

In 2010, Bouey and her team synthesized 3-(p-tolyloxy)phenol from 3-iodoanisole and p-methylphenol through a two-step process (Scheme 14). The first step involved etherification utilizing copper iodide, N,N-dimethylglycine hydrochloride, and cesium carbonate. The second step involved demethylation through the use of boron tribromide and DCM as solvents [51].


Scheme 14. Synthesis of 3-(p-tolyloxy)phenol based on copper iodide as a catalyst.

The 3-(p-tolyloxy)phenol was then used to synthesize polysubstituted imidazolone derivatives, which possess peroxisome proliferator-activated receptor (PPAR) agonist properties and can be used for the treatment of certain conditions related to lipid and glucose metabolism disorders, as well as hypertension. These conditions include metabolic syndrome, diabetes, dyslipidemias (abnormal levels of lipids in the blood), and obesity, which can all increase the risk of developing cardiovascular diseases [51,52].

Lee and his team reported a method for the synthesis of 3-(4-bromophenoxy)phenol, a meta-substituted phenol derivative, using the Ullmann coupling reaction (Scheme 15). The reaction involved the use of copper iodide, potassium carbonate, and L-proline as catalysts and was conducted in DMSO [53].

Scheme 15. Synthesis of 3-(4-bromophenoxy)phenol.

The synthesized 3-(4-bromophenoxy)phenol was then utilized as a component in the fabrication of an organic light-emitting device (OLED) [54]. OLEDs consist of two electrodes and an organic layer that contains at least one organometallic compound, and they are known for their self-emissive properties that result in full-color images with high brightness, high contrast ratios, and wide viewing angles [53].

In 2012, Li and his team reported a two-step synthesis of bisphenol monomers from 4,4′-dibromo biphenyl and 3-methoxyphenol using a copper catalyst (Scheme 16). The intermediate methoxy-terminated four-ring monomer was hydrolyzed using hydrobromic acid in acetic acid to produce alcohols. Both steps required high-temperature conditions of 165 °C for the first step and 150 °C for the second [55].

**Scheme 16.** Synthesis of bisphenol using a copper catalyst.

The resulting bisphenol monomers were used to prepare novel ionic aromatic polymers with precisely sequenced ionic moieties that contained one or two sulfonic acid groups along the backbone. Sulfonated aromatic hydrocarbon polymers have garnered attention as potential candidates for membranes in the production of electrical power and clean water [55,56].

In 2013, Bartholomeus et al. published a report on the synthesis of 3-(3,5-dimethoxyphenoxy)phenol using the Ullmann-type coupling reaction (Scheme 17). The process involved combining 1-bromo-3,5-dimethoxybenzene with resorcinol in the presence of a copper iodide catalyst, N, N-dimethylglycine hydrochloride, cesium carbonate, and DMF as the solvent [57].

Scheme 17. Synthesis of 3-(3,5-dimethoxyphenoxy)phenol.

The resulting product obtained from the synthesis process was an intermediate in the creation of fulicineroside. This compound demonstrated moderate inhibition against *Staphylococcus aureus* and *Bacillus subtilis*. Additionally, it was found to have significant inhibitory effects on crown gall tumors, suggesting its potential as an anti-tumor agent [57,58].

The authors of [59] describe a method for obtaining 1,3-di(3-hydroxyphenoxy)benzene which includes two stages. This method is a modified form of the process published by Wang [60]. Thus, at the first stage, 1,3-diaryl-substituted products are produced through the interaction of various activated m-cresols with protected hydroxy groups with compounds containing leaving groups (LG) in the meta position in the presence of a catalyst such as copper (I) chloride. Further interaction of these compounds with an acid catalyst leads to the formation of 1,3-di(3-hydroxyphenoxy)benzene (Scheme 18).

P – a protecting group (acetyl, benzoyl, benzyl, methoxymethyl ether, methoxytrityl and others);
M - a metal (K, Na);
LG - a leaving group (I, Br, Cl, or sulfonate ester groups)

1,3-Bis(3-hydroxyphenoxy)benzene

Scheme 18. Synthesis of 1,3-di(3-hydroxyphenoxy)benzene.

Protecting groups, which can be temporary or permanent, are known by their art, and methods for their installation and removal are described in standard references [61], the contents of which are incorporated by reference. Hydroxyl groups can be protected using groups (P) such as acetyl, benzoyl, benzyl, methoxymethyl, methoxytrityl, methylthiomethyl, pivaloyl, tetrahydropyranyl, tetrahydrofuran, trityl, silyl (including trimethylsilyl, tert-butyldimethylsilyl, tri-isopropylsilyloxymethyl, and triisopropylsilyl), alkyl (such as methyl ethers), and ethoxyethyl.

1,3-Di(3-hydroxyphenoxy)benzene is the basis of epoxy resins with high resistance to deformation. Epoxy resins are versatile materials that can be combined with fibers to produce a variety of composite materials, including a raft of prepreg compositions.

In 2015, Gim et al. published a method for synthesizing 3-(p-substituted aryloxy) phenols through an Ullmann coupling reaction. This reaction involved combining resorcinol with aryl iodides using CuI and picolinic acid as catalysts (Scheme 19). The resulting compounds were then utilized to develop a new series of alkoxy-3-indolylacetic acid analogs, which showed potential as PPAR agonists. These compounds have been tested for treating dyslipidemia, obesity, and insulin resistance in clinical trials [62,63].

Resorcinol, CuI, picolinic acid,
K$_3$PO$_4$, DMSO
90°C overnight

R= -OH, -CH$_3$, -Cl
-CF$_3$,-OCH$_3$

Scheme 19. Synthesis of 3-(p-substituted aryloxy) phenols using CuI and picolinic acid as catalysts.

In 2016, Yang and his colleagues introduced a four-step method for synthesizing 3-(3,5-dichloro-4-hydroxyphenoxy)phenol from 4-iodophenol (Scheme 20). The process involves the Ullmann reaction catalyzed by copper and using 3-methoxyphenol as a co-reagent, followed by demethylation with HBr in acetic acid. All steps require an inert atmosphere and exhibit high yields. The same procedure was also used to synthesize 3-(3,5-dichloro-4-hydroxyphenoxy)-4-chlorophenol. This process was described by Hu and his group in 2016 [64,65].

Scheme 20. Synthesis of 3-(3,5-dichloro-4-hydroxyphenoxy)phenol and 3-(3,5-dichloro-4-hydroxyphenoxy)-4-chlorophenol.

The resulting compound was utilized to create compounds aimed at enhancing fluorogenic probes for measuring, detecting, and screening hypochlorous acid or hydroxyl radicals in biological and chemical samples, such as cells and tissues within living organisms [63].

In 2017, Bai and his team published a two-step synthesis of 3-(3,5-diiodo-4-hydroxyphenoxy)phenol and 3-(3,5-diiodo-4-hydroxyphenoxy)-4-chlorophenol from 2,4,6-triiodophenol with corresponding reagents. The final step involved using boron tribromide in DCM as a demethylation agent (Scheme 21) [66].

Scheme 21. Synthesis of 3-(3,5-diiodo-4-hydroxyphenoxy)phenol and 3-(3,5-diiodo-4-hydroxyphenoxy)-4-chlorophenol.

The resulting compounds were utilized to create a highly sensitive and selective probe, HKOH-1, which had an ability to monitor hydroxyl (-OH) formation in live cells that was improved by >30-fold [66,67].

According to the patent by Breitenburcher and colleagues in 2010 [68], the desired compounds were synthesized by treatment of the appropriate starting material with a

CuI solution in the presence of resorcinol, dimethylglycine HCl, and cesium carbonate in N,N-dimethylacetamide (DMA) (Scheme 22).

Scheme 22. Synthesis of 3-(p-substituted aryloxy)phenols using CuI and DMG*HCl as catalysts.

The resulting products were utilized as intermediate reagents in the synthesis of aryl-substituted heterocyclic urea derivatives, which possessed the ability to modulate the activity of fatty acid amide hydrolase (FAAH). The authors described methods of utilizing these aryl-substituted heterocyclic urea derivatives in the treatment of various disease states and disorders [68].

4. Sonogashira Coupling: A Copper-Catalyzed Method for Biaryl Synthesis

The Sonogashira coupling reaction represents a variation of cross-coupling, wherein the interaction between aryl boronic acids and phenols is facilitated by the presence of a copper catalyst and a base. Copper (II) acetate ($Cu(OAc)_2$) serves as a typical example of a copper catalyst for this reaction, while potassium carbonate (K_2CO_3) is commonly used as the base. The reaction mechanism involves the formation of a complex between the copper and the phenol, which subsequently reacts with the aryl boronic acid to form an intermediate. This intermediate undergoes transmetallation to furnish the final biaryl product. Due to its high efficiency and versatility, the Sonogashira coupling reaction has gained widespread use in the synthesis of pharmaceuticals and agrochemicals, among other applications [69,70].

A report by Bryan and colleagues in 2015 summarizes research endeavors centered on forming new carbon-heteroatom bonds using organoboron reagents through copper acetate-mediated reactions under ultrasound irradiation (Scheme 23). The methodology involved incorporating ultrasound irradiation in the Chan–Evans–Lam reaction to achieve the O-arylation of phenols, the N-arylation of anilines and indoles, and the S-arylation of thiols. The utilization of ultrasound irradiation was discovered to significantly reduce the reaction times from 72 h to 4 h while increasing product yields by an average of 20% [71].

Scheme 23. Synthesis of new aryloxy phenols using the Sonogashira reaction.

Scientists at the University of Pisa described a method for producing new diaryl ether phenolic compounds, which are two peripheral phenolic rings with hydroxyl groups in the meta- and/or para-position, which are connected by a central 1,3-disubstituted phenyl ring. The synthesis of these compounds included four stages (Scheme 24).

The synthesis was started with commercially available 3-bromophenol, which is subjected to a cross-coupling reaction under bis(triphenylphosphine)palladium-catalyzed Suzuki conditions with 3- or 4-methoxybenzene boronic acid to obtain diaryl derivatives—3- and 4-phenoxy anisole in quantitative yield (99%) (Scheme 24, stage 1). The catalyst was obtained by mixing a solution of palladium acetate $Pd(OAc)_2$ and triphenylphosphine

(PPh$_3$) in ethanol and toluene at room temperature in an inert gas environment. The formation of a C–O bond interaction of these intermediates with 3- and 4-bromanisole was carried out in the presence of appropriate catalysts during heating. In fact, they reacted in a ligand-free Ullmann-type reaction with 4-bromoanisole and forms 3- and 4-methoxy substituted derivatives of diaryl ether (Scheme 24, stages 2 and 3). All the methoxy-substituted derivatives were subjected to a common last synthetic step, consisting of a BBr$_3$-promoted removal of the methyl groups, in order to obtain the desired diaryl ether phenolic compounds (Scheme 24, stage 4). The use of this dealkylating agent provided good yields of the target products (yield 71–95%) [72].

Scheme 24. Synthesis of new diaryl ether phenolic compounds.

The synthesized diaryl ether phenolic compounds were able to activate the human enzyme SIRT1 and regulate many metabolic functions. They can be used for medical applications, specifically for the treatment or prevention of cardiometabolic diseases such as diabetes, heart failure, and atherosclerosis.

5. Synthesis of m-Aryloxy Phenols Using Grignard Reagents

The utilization of Grignard reagents, which are a type of organometallic compound, in the synthesis of aryloxy phenols via a reaction with aldehydes or ketones has received widespread attention in the field of organic chemistry. Through interaction with a carbonyl compound, a complex intermediate is formed, which, upon treatment with acidic conditions, gives rise to the corresponding alcohol. The alcohol can then be oxidized through the use of oxidation reagents such as hydrogen peroxide (H$_2$O$_2$) or sodium hypochlorite (NaClO) to produce the desired aryloxy phenol.

It is important to note that the reaction conditions, such as the choice of solvent and the presence of catalysts or bases, have a significant impact on the reactivity, selectivity, yield, and stereochemistry of the Grignard reaction, as well as the final product [73].

In 2012, researchers led by Pidathala used 4-(3-methoxyphenoxy)benzaldehyde in a Grignard reaction to produce an intermediate alcohol (Scheme 25).

Scheme 25. Synthesis of 1-[4-(3-hydroxyphenoxy)phenyl]propan-1-one.

The alcohol was then oxidized using PCC to obtain 1-(4-(3-methoxyphenoxy)phenyl) propane-1-one with a yield of 89%. BBr$_3$ was utilized to remove the methyl and produce 1-[4-(3-hydroxyphenoxy)phenyl]propane-1-one with a yield of 62% [74].

The resulting compound was used to synthesize a series of bisaryl quinolones with potent antimalarial activity. The lead compounds in this series showed antimalarial activity against the 3D7 strain of P. falciparum and had low nanomolar PfNDH2 activity [74,75].

Gao and colleagues synthesized 3-(4-fluorophenoxy)phenol from arylmetals via hydroxylation using N-benzyl oxaziridine. The reaction proceeded at room temperature for a duration of 2 h. The authors demonstrated that bench-stable N−H and N−alkyl oxaziridines, derived from economical terpenoid scaffolds, can act as effective primary aminating and hydroxylating reagents, producing primary arylamines and phenols directly from readily available aryl-metals in the absence of transition-metal catalysts and under exceptionally mild conditions (Scheme 26) [76].

Scheme 26. Synthesis of 3-(4-fluorophenoxy)phenol.

6. Hydrolysis of Diazonium Salts Using a Two-Phase System

In 2015, Taniguchi et al. published findings on the synthesis of 3-phenoxyphenol and 3-(4-nitrophenoxy)phenol (Scheme 27). The method involved the hydrolysis of intermediate diazonium salts derived from anilines in a two-phase system of cyclopentyl methyl ether (CPME) and water, resulting in high yields of the desired compounds.

Scheme 27. Synthesis of 3-phenoxyphenol and 3-(4-nitrophenoxy)phenol.

These products were found to be key components for the production of raw materials for functional plastics, specifically polyimide resin [77].

7. Synthesis of 3-Aryloxyphenols from 3-Chlorocyclohex-2-en-1-one

In 2023, a chemical reaction was reported by Clive et al. wherein 3-chlorocyclohex-2-en-1-one was treated with phenols in the presence of K_2CO_3, resulting in the formation of 3-(aryloxy)cyclohex-2-en-1-ones. The synthesized products were then subjected to bromination at the C(2) position and using NBS in DMF, which ultimately formed the brominated products. Subsequently, the brominated compounds were aromatized to form 3-(aryloxy)phenols through a treatment with DBU in PhMe or MeCN. This multi-step reaction sequence necessitated the use of several reagents and conditions to generate the final compounds (Scheme 28). The method presently utilized operates at ambient temperature and does not employ any heavy metals or ligands. Moreover, it circumvents the procedural steps required to overcome the o,p-directing effect of oxygen, owing to the readily available 1,3-functional group relationship inherent in the starting material, namely cyclohexane-1,3-dione [78].

Ar =	Yields of FC, %
Ph	86
2-MeC_6H_4	77
4-MeC_6H_4	73
4-IC_6H_4	58
4-ClC_6H_4	80
Naphtalen-1-yl	54
2,6-(MeO)_2C_6H_4	75
2-t-BuC_6H_4	78
4-t-BuC_6H_4	86
2-(MeO)C_6H_4	85
4-(MeO)C_6H_4	89
3-(PhO)C_6H_4	94
3,5-Me_2C_6H_4	87
4-(MeO_2C)C_6H_4	57

Scheme 28. Synthesis of 3-aryloxyphenols from 3-chlorocyclohex-2-en-1-one.

8. Conclusions

In summary, the past decade has born witness to remarkable advances in the synthesis and utilization of m-aryloxy phenols. The implementation of various synthetic methodologies has resulted in the preparation of structurally diverse m-aryloxy phenols, including biologically active compounds with promising pharmacological applications. Moreover, m-aryloxy phenols have demonstrated versatility in the fields of materials science and organic electronics. These achievements have propelled further research on the synthesis, characterization, and application of m-aryloxy phenols, and it is anticipated that this research area will continue to expand in the foreseeable future. The growing interest in m-aryloxy phenols underscores their potential to emerge as key compounds in the field of synthetic organic chemistry and their relevance to a diverse range of technological applications.

Author Contributions: All authors conceptualized and designed this study: D.A., G.B. and M.D.—writing, review and editing; D.A., G.B., B.K., A.S., D.Z. and M.D.—drafting and revision of the manuscript. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Latha, G.; Devarajan, N.; Karthik, M.; Suresh, P. Nickel-Catalyzed Oxidative Hydroxylation of Arylboronic Acid: Ni(HBTC)BPY MOF as an Efficient and Ligand-Free Catalyst to Access Phenolic Motifs. *Catal. Commun.* **2020**, *136*, 105911. [CrossRef]
2. Wang, S.K.; Chen, M.T.; Zhao, D.Y.; You, X.; Luo, Q.L. Iodine-Catalyzed Oxidative Aromatization: A Metal-Free Concise Approach to meta-Substituted Phenols from Cyclohex-2-enones. *Adv. Synth. Catal.* **2016**, *358*, 4093–4099. [CrossRef]
3. Ullmann, F. Ueber eine neue Bildungsweise von Diphenylaminderivaten. *Ber. Der Dtsch. Chem. Ges.* **1903**, *36*, 2382–2384. [CrossRef]
4. Ullmann, F. Ueber eine neue Darstellungsweise von Phenyläthersalicylsäure. *Ber. Der Dtsch. Chem. Ges.* **1904**, *37*, 853–854. [CrossRef]
5. Hassan, J.; Sévignon, M.; Gozzi, C.; Schulz, E.; Lemaire, M. Aryl-aryl Bond Formation One Century after the Discovery of the Ullmann Reaction. *Chem. Rev.* **2002**, *102*, 1359–1470. [CrossRef] [PubMed]
6. Zuo, L.; Yao, S.; Wang, W.; Duan, W. An Efficient Method for Demethylation of Aryl Methyl Ethers. *Tetrahedron Lett.* **2008**, *49*, 4054–4056. [CrossRef]
7. Bradsher, C.K.; Brown, F.C.; Porter, H.K. Synthesis and Fungistatic Activity of Some 3-Hydroxybiphenyl Derivatives. *J. Am. Chem. Soc.* **1954**, *76*, 2357–2362. [CrossRef]
8. McOmie, J.F.W.; Watts, M.L.; West, D.E. Demethylation of Aryl Methyl Ethers by Boron Tribromide. *Tetrahedron* **1968**, *24*, 2289–2292. [CrossRef]
9. Kormos, C.M.; Jin, C.; Cueva, J.P.; Runyon, S.P.; Thomas, J.B.; Brieaddy, L.E.; Mascarella, S.W.; Navarro, H.A.; Gilmour, B.P.; Carroll, F.I. Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl] methyl-2-methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists. *J. Med. Chem.* **2013**, *56*, 4551–4567. [CrossRef]
10. Carroll, F.I.; Carlezon Jr, W.A. Development of κ Opioid Receptor Antagonists. *J. Med. Chem.* **2013**, *56*, 2178–2195. [CrossRef]
11. Puls, K.; Olivé-Marti, A.L.; Pach, S.; Pinter, B.; Erli, F.; Wolber, G.; Spetea, M. In Vitro, In Vivo and In Silico Characterization of a Novel Kappa-Opioid Receptor Antagonist. *Pharmaceuticals* **2022**, *15*, 680. [CrossRef] [PubMed]
12. Yamamoto, Y.; Tago, T.; Toyohara, J.; Saito, Y.; Yamamoto, F. Radiosynthesis and in Vivo and ex Vivo Evaluation of Isomeric [11C] methoxy Analogs of Nimesulide as Brain Cyclooxygenase-2-Targeted Imaging Agents. *Biol. Pharm. Bull.* **2022**, *45*, 94–103. [CrossRef] [PubMed]
13. Yamamoto, Y.; Hisa, T.; Arai, J.; Saito, Y.; Yamamoto, F.; Mukai, T.; Ohshima, T.; Maeda, M.; Ohkubo, Y. Isomeric Methoxy Analogs of Nimesulide for Development of Brain Cyclooxygenase-2 (COX-2)-Targeted Imaging Agents: Synthesis, In Vitro COX-2-Inhibitory Potency, and Cellular Transport Properties. *Bioorg. Med. Chem.* **2015**, *23*, 6807–6814. [CrossRef]
14. Yang, F.; Zhao, J.; Li, Y.; Zhang, S.; Shao, Y.; Shao, H.; Ma, T.; Gong, C. Synthesis and Properties of Novel Organosoluble Polyimides Derived from Bis [3-(4-Amino-2-trifluoromethylphenoxy)phenyl] Ether. *Eur. Polym. J.* **2009**, *45*, 2053–2059. [CrossRef]
15. Van Rossom, W.; Robeyns, K.; Ovaere, M.; Van Meervelt, L.; Dehaen, W.; Maes, W. Odd-Numbered Oxa-Calix[n]arenes (n= 5, 7): Synthesis and Solid-State Structures. *Org. Lett.* **2011**, *13*, 126–129. [CrossRef]
16. Danil de Namor, A.F.; Aparicio-Aragon, W.; Nwogu, N.; El Gamouz, A.; Piro, O.E.; Castellano, E.E. Calixarene and Resorcarene Based Receptors: From Structural and Thermodynamic Studies to the Synthesis of a New Mercury (II) Selective Material. *J. Phys. Chem. B* **2011**, *115*, 6922–6934. [CrossRef]
17. Uysal Akku, G.; Al, E.; Korcan, S.E. Selective Extraction of Toxic Heavy Metals and Biological Activity Studies Using Pyrimidylthioamide Functionalised Calix[4]arene. *Supramol. Chem.* **2015**, *27*, 522–526. [CrossRef]
18. Patra, S.; Maity, D.; Gunupuru, R.; Agnihotri, P.; Paul, P. Calixarenes: Versatile Molecules as Molecular Sensors for Ion Recognition Study. *J. Chem. Sci.* **2012**, *124*, 1287–1299. [CrossRef]
19. Raynal, M.; Ballester, P.; Vidal-Ferran, A.; Van Leeuwen, P.W. Supramolecular Catalysis. Part 2: Artificial Enzyme Mimics. *Chem. Soc. Rev.* **2014**, *43*, 1734–1787. [CrossRef]
20. Baldini, L.; Cacciapaglia, R.; Casnati, A.; Mandolini, L.; Salvio, R.; Sansone, F.; Ungaro, R. Upper Rim Guanidinocalix[4]arenes as Artificial Phosphodiesterases. *J. Org. Chem.* **2012**, *77*, 3381–3389. [CrossRef] [PubMed]
21. da Silva, D.L.; Fernandes, S.A.; Sabino, A.A.; de Fátima, Â. p-Sulfonic Acid Calixarenes as Efficient and Reusable Organocatalysts for the Synthesis of 3,4-Dihydropyrimidin-2(1H)-ones/-thiones. *Tetrahedron Lett.* **2011**, *52*, 6328–6330. [CrossRef]
22. Lindley, J. Copper Assisted Nucleophilic Substitution of Aryl Halogen. *Tetrahedron* **1984**, *40*, 1433–1456. [CrossRef]
23. Vagin, S.I.; Reichardt, R.; Klaus, S.; Rieger, B. Conformationally flexible dimeric salphen complexes for bifunctional catalysis. *J. Am. Chem. Soc.* **2010**, *132*, 14367–14369. [CrossRef] [PubMed]
24. Cui, L.; Ren, B.H.; Lu, X.B. Trinuclear Salphen–Chromium (III) Chloride Complexes as Catalysts for the Alternating Copolymerization of Epoxides and Cyclic Anhydrides. *J. Polym. Sci.* **2021**, *59*, 1821–1828. [CrossRef]
25. Wang, J.; Hu, J.; Zeng, K.; Yang, G. Preparation of self-promoted hydroxy-containing phthalonitrile resins by an in situ reaction. *RSC Adv.* **2015**, *5*, 105038–105046. [CrossRef]
26. Zu, Y.; Zong, L.; Wang, J.; Jian, X. Enhanced Thermal Property via Tunable Bisphenol Moieties in Branched Phthalonitrile Thermoset. *Polymer* **2019**, *172*, 372–381. [CrossRef]
27. Bollini, M.; Domaoal, R.A.; Thakur, V.V.; Gallardo-Macias, R.; Spasov, K.A.; Anderson, K.S.; Jorgensen, W.L. Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. *J. Med. Chem.* **2011**, *54*, 8582–8591. [CrossRef]

28. Pauwels, R. New Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in Development for the Treatment of HIV Infections. *Curr. Opin. Pharmacol.* **2004**, *4*, 437–446. [CrossRef]

29. Frey, K.M.; Gray, W.T.; Spasov, K.A.; Bollini, M.; Gallardo-Macias, R.; Jorgensen, W.L.; Anderson, K.S. Structure-Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV-1 Reverse Transcriptase. *Chem. Biol. Drug Des.* **2014**, *83*, 541–549. [CrossRef]

30. Huang, B.; Chen, W.; Zhao, T.; Li, Z.; Jiang, X.; Ginex, T.; Vilchez, D.; Luque, F.J.; Kang, D.; Gao, P.; et al. Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. *J. Med. Chem.* **2019**, *62*, 2083–2098. [CrossRef]

31. Xia, Y.; Cao, K.; Zhou, Y.; Alley, M.R.K.; Rock, F.; Mohan, M.; Meewan, M.; Baker, S.J.; Lux, S.; Ding, C.Z.; et al. Synthesis and SAR of novel benzoxaboroles as a new class of β-lactamase inhibitors. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2533–2536. [CrossRef]

32. Xiao, Y.C.; Chen, X.P.; Deng, J.; Yan, Y.H.; Zhu, K.R.; Li, G.; Yu, J.L.; Brem, J.; Chen, F.; Schofield, C.J.; et al. Design and Enantioselective Synthesis of 3-(α-Acrylic Acid) Benzoxaboroles to Combat Carbapenemase Resistance. *Chem. Commun.* **2021**, *57*, 7709–7712. [CrossRef]

33. Kobayashi, O.; Niikura, N.; Inoue, T.; Mizuta, S.; Takatsuna, R.; Hirai, K.; Shirouzu, K.; Kaken Pharmaceutical Co., Ltd. Sagami Chemical Research Institute (Sagami CRI). Polycyclic Pyrazolinone Derivative and Herbicide Comprising Same as Effective Component Thereof. U.S. Patent 9580444, 28 February 2017.

34. Chen, P.; Shi, M.; Niu, M.; Zhang, Y.; Wang, R.; Xu, J.; Wang, Y. Effects of HPPD Inhibitor Herbicides on Soybean Root Exudates: A Combination Study of Multispectral Technique and 2D-COS Analysis. Spectrochim. *Acta Part A Mol. Biomol. Spectrosc.* **2023**, *289*, 122241. [CrossRef]

35. Kazui, Y.; Fujii, S.; Yamada, A.; Ishigami-Yuasa, M.; Kagechika, H.; Tanatani, A. Structure-activity relationship of novel (benzoylaminophenoxy) phenol derivatives as anti-prostate cancer agents. *Bioorg. Med. Chem.* **2018**, *26*, 5118–5127. [CrossRef] [PubMed]

36. Elancheran, R.; Kabilan, S.; Kotoky, J.; Ramanathan, M.; Bhattacharjee, A. In Silico Molecular Docking, Synthesis of 4-(4-Benzoylaminophenoxy) Phenol Derivatives as Androgen Receptor Antagonists. *Comb. Chem. High Throughput Screen.* **2019**, *22*, 307–316. [CrossRef]

37. Silva, M.E.T.D.; Martins, M.A.; Leite, M.D.O.; Milião, G.L.; Coimbra, J.S.D.R. Microalga Scenedesmus obliquus: Extraction of Bioactive Compounds and Antioxidant Activity. *Rev. Ciência Agronômica* **2021**, *52*, e20196848. [CrossRef]

38. Frączek, T.; Kamiński, R.; Krakowiak, A.; Naessens, E.; Verhasselt, B.; Paneth, P. Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility. *J. Enzym. Inhib. Med. Chem.* **2018**, *33*, 9–16. [CrossRef]

39. Huang, B.; Kang, D.; Yang, J.; Zhan, P.; Liu, X. Novel Diarylpyrimidines and Diaryltriazines as Potent HIV-1 NNRTIs with Dramatically Improved Solubility: A Patent Evaluation of US20140378443A1. *Expert Opin. Ther. Pat.* **2016**, *26*, 281–289. [CrossRef] [PubMed]

40. Prener, L.; Baszczyňski, O.; Kaiser, M.M.; Dračínský, M.; Stepan, G.; Lee, Y.J.; Brumshtein, B.; Yu, H.; Jansa, P.; Lansdon, E.B.; et al. Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties. *J. Med. Chem.* **2023**, *66*, 1761–1777. [CrossRef] [PubMed]

41. Zhong, Y.L.; Ji, Y.; Wang, H.; Wang, X.; Gauthier Jr, D.R. Highly Enantioselective Rhodium-Catalyzed Transfer Hydrogenation of Tetrasubstituted Olefins: Application toward the Synthesis of GPR40 Agonist MK-2305. *Org. Lett.* **2022**, *24*, 3254–3258. [CrossRef] [PubMed]

42. Pio, B.; Chobanian, H.R.; Guo, Y.; Josien, H.; Hagmann, W.K.; Miller, M.; Trujillo, M.E.; Kirkland, M.; Kosinski, D.; Mane, J.; et al. Design, Synthesis and Biological Evaluation of Indane Derived GPR40 AgoPAMs. *Bioorg. Med. Chem. Lett.* **2019**, *29*, 1842–1848. [CrossRef] [PubMed]

43. Joseph, P.J.A.; Priyadarshini, S. Copper-Mediated C–X Functionalization of Aryl Halides. *Org. Process Res. Dev.* **2017**, *21*, 1889–1924. [CrossRef]

44. Sperotto, E.; van Klink, G.P.M.; van Koten, G.; de Vries, J.G. The Mechanism of the Modified Ullmann Reaction. *Dalton Trans.* **2010**, *39*, 10338–10351. [CrossRef]

45. Lin, H.; Sun, D. Recent synthetic developments and applications of the ullmann reaction. *Rev. Org. Prep. Proced. Int.* **2013**, *45*, 341–394. [CrossRef]

46. Khan, F.; Dlugosch, M.; Liu, X.; Banwell, M.G. The Palladium-Catalyzed Ullmann Cross-Coupling Reaction: A Modern Variant on a Time-Honored Process. *Acc. Chem. Res.* **2018**, *51*, 1784–1795. [CrossRef]

47. Xue, F.; Huang, J.; Ji, H.; Fang, J.; Li, H.; Martásek, P.; Roman, L.J.; Poulos, T.L.; Silverman, R.B. Structure-based design, synthesis, and biological evaluation of lipophilic-tailed monocationic inhibitors of neuronal nitric oxide synthase. *Bioorganic Med. Chem.* **2010**, *18*, 6526–6537. [CrossRef]

48. Mukherjee, P.; Cinelli, M.A.; Kang, S.; Silverman, R.B. Development of Nitric Oxide Synthase Inhibitors for Neurodegeneration and Neuropathic Pain. *Chem. Soc. Rev.* **2014**, *43*, 6814–6838. [CrossRef] [PubMed]

49. Sapkota, K.; Lee, E.Y.; Yang, J.H.; Kwon, Y.J.; Choi, J.W.; Na, Y.H. 4-Hydroxy-2′-nitrodiphenyl ether analogues as novel tyrosinase inhibitors. *Bull. Korean Chem. Soc.* **2010**, *31*, 1319–1325. [CrossRef]

50. Sholehvar, F.; Asadzadeh, A.; Seyedhosseini, H. Molecular Docking Studies of Some Hydroxy Nitrodiphenyl Ether Analogues as Tyrosinase Inhibitors. *J. Fasa Univ. Med. Sci.* **2017**, *6*, 548–555.

51. Bouey, E.; Masson, C.; Bertrand, K. Substituted Imidazolone Derivatives, Preparations and Uses. U.S. Patent 2010/0004159 A1, 7 January 2010.

52. Takada, I.; Makishima, M. Peroxisome Proliferator-Activated Receptor Agonists and Antagonists: A Patent Review (2014-Present). *Expert Opin. Ther. Pat.* **2020**, *30*, 1–13. [CrossRef]

53. Lee, J.; Kim, S.; Ko, S.; Kim, H.; Shin, S.; Ahn, E.; Lee, E.; Lee, H.; Jeon, M.; Han, J. Organometallic Compound and Organic Light-Emitting Device Including the Same. U.S. Patent 2021/36228, 4 February 2021.

54. Xiao, L.; Chen, Z.; Qu, B.; Luo, J.; Kong, S.; Gong, Q.; Kido, J. Recent Progresses on Materials for Electrophosphorescent Organic Light-Emitting Devices. *Adv. Mater.* **2011**, *23*, 926–952. [CrossRef]

55. Li, X.F.; Paoloni, F.P.; Weiber, E.A.; Jiang, Z.H.; Jannasch, P. Fully aromatic ionomers with precisely sequenced sulfonated moieties for enhanced proton conductivity. *Macromolecules* **2012**, *45*, 1447–1459. [CrossRef]

56. Khomein, P.; Ketelaars, W.; Lap, T.; Liu, G. Sulfonated Aromatic Polymer as a Future Proton Exchange Membrane: A Review of Sulfonation and Crosslinking Methods. *Renew. Sustain. Energy Rev.* **2021**, *137*, 110471. [CrossRef]

57. Bartholomäus, R.; Dommershausen, F.; Thiele, M.; Karanjule, N.S.; Harms, K.; Koert, U. Total synthesis of the postulated structure of fulicineroside. *Chem. Eur. J.* **2013**, *19*, 7423–7436. [CrossRef] [PubMed]

58. Yang, Y.; Zhang, X.; Yu, B. O-Glycosylation Methods in the Total Synthesis of Complex Natural Glycosides. *Nat. Prod. Rep.* **2015**, *32*, 1331–1355. [CrossRef] [PubMed]

59. Varley, R.J.; Dao, N.B.; Tian, W.W.; Christensen, S.; Tucker, S.; Wiggins, J. Epoxy Resin. International Patent WO 2018/018070 AI, 1 February 2018.

60. Wang, L.; Xi, H.; Sun, X.; Shen, Y.; Yang, Y.; Pan, Y.; Hu, H. Synthesis of Functionalized p-Phenylene Oxide Oligomers. *Synth. Commun.* **2000**, *30*, 227–234. [CrossRef]

61. Greene, T.W.; Wuts, P.G.M. *Protecting Groups in Organic Synthesis*, 2nd ed.; John Wiley & Sons: New York, NY, USA, 1991.

62. Gim, H.J.; Li, H.; Jeong, J.H.; Lee, S.J.; Sung, M.K.; Song, M.Y.; Park, B.H.; Oh, S.J.; Ryu, J.H.; Jeon, R. Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor γ/δ agonists. *Bioorg. Med. Chem.* **2015**, *23*, 3322–3336. [CrossRef] [PubMed]

63. Gim, H.J.; Choi, Y.S.; Li, H.; Kim, Y.J.; Ryu, J.H.; Jeon, R. Identification of a Novel PPAR-γ Agonist through a Scaffold Tuning Approach. *Int. J. Mol. Sci.* **2018**, *19*, 3032. [CrossRef] [PubMed]

64. Yang, D.; Hu, J.; Wong, N.; Bai, X. Diarylether-Based Fluorogenic Probes for Detection of Hypochlorous Acid or Hydroxyl Radical. U.S. Patent 20160312033A1, 27 October 2016.

65. Hu, J.J.; Wong, N.K.; Lu, M.Y.; Chen, X.; Ye, S.; Zhao, A.Q.; Gao, P.; Kao, R.Y.T.; Shen, J.; Yang, D. HKOCl-3: A fluorescent hypochlorous acid probe for live-cell and in vivo imaging and quantitative application in flow cytometry and a 96-well microplate assay. *Chem. Sci.* **2016**, *7*, 2094–2099. [CrossRef]

66. Bai, X.; Huang, Y.; Lu, M.; Yang, D. HKOH-1: A highly sensitive and selective fluorescent probe for detecting endogenous hydroxyl radicals in living cells. *Angew. Chem. Int. Ed.* **2017**, *56*, 12893–12897. [CrossRef]

67. Li, M.D.; Wong, N.K.; Xiao, J.; Zhu, R.; Wu, L.; Dai, S.Y.; Chen, F.; Huang, G.; Xu, L.; Bai, X.; et al. Dynamics of Oxygen-Independent Photocleavage of Blebbistatin as a One-Photon Blue or Two-Photon Near-Infrared Light-Gated Hydroxyl Radical Photocage. *J. Am. Chem. Soc.* **2018**, *140*, 15957–15968. [CrossRef]

68. Breitenbucher, G.J.; Tichenor, M.S.; Merit, J.E.; Hawryluk, N.A.; Chambers, A.L.; Keith, J.M. Aryl-Substituted Heterocyclic Urea Modulators of Fatty Acid Amide Hydrolase. U.S. Patent WO 2010/141809 A1, 9 December 2010.

69. Thomas, A.M.; Sujatha, A.; Anilkumar, G. Recent Advances and Perspectives in Copper-Catalyzed Sonogashira Coupling Reactions. *RSC Adv.* **2014**, *4*, 21688–21698. [CrossRef]

70. Min, H.; Palani, T.; Park, K.; Hwang, J.; Lee, S. Copper-Catalyzed Direct Synthesis of Diaryl 1, 2-Diketones from Aryl Iodides and Propiolic Acids. *J. Org. Chem.* **2014**, *79*, 6279–6285. [CrossRef] [PubMed]

71. Bryan, J.M.; George, W.K. Copper mediated formation of carbon-heteroatom bonds using organoboron reagents and ultrasound. *Heterocycles Int. J. Rev. Commun. Heterocycl. Chem.* **2015**, *90*, 271–297.

72. Calderone, V.; Minutolo, F.; Tuccinardi, T.; Testai, L.; Granchi, C.; Martelli, A.; Citi, V.; De Lorenzo, C.V.; Lenzi, G.; Leo, F.; et al. New Activators of SIRT1 Enzyme for the Treatment of Cardiovascular and Cardiometabolic Pathologies. International Patent WO 2019/162911, 29 August 2019.

73. Mann, F.G.; Stewart, F.H. The Action of Magnesium and of Grignard Reagents on Certain Benzyl Ethers. Part I. The Action of Magnesium on o-, m-, and p-Alkoxy-and-phenoxy-methylbenzyl Chlorides. *J. Chem. Soc.* **1954**, 2826–2832. [CrossRef]

74. Pidathala, C.; Amewu, R.; Pacorel, B.; Nixon, G.L.; Gibbons, P.; Hong, W.D.; Leung, S.C.; Berry, N.G.; Sharma, R.; Stocks, P.A.; et al. Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH: Quinone oxidoreductase (PfNDH2). *J. Med. Chem.* **2012**, *55*, 1831–1843. [CrossRef]

75. Amporndanai, K.; Pinthong, N.; O'Neill, P.M.; Hong, W.D.; Amewu, R.K.; Pidathala, C.; Berry, N.G.; Leung, S.C.; Ward, S.A.; Biagini, G.A.; et al. Targeting the Ubiquinol-Reduction (Qi) Site of the Mitochondrial Cytochrome bc1 Complex for the Development of Next Generation Quinolone Antimalarials. *Biology* **2022**, *11*, 1109. [CrossRef] [PubMed]

76. Gao, H.; Zhou, Z.; Kwon, D.H.; Coombs, J.; Jones, S.; Behnke, N.E.; Ess, D.H.; Kürti, L. Rapid heteroatom transfer to arylmetals utilizing multifunctional reagent scaffolds. *Nat. Chem.* **2017**, *9*, 681–688. [CrossRef] [PubMed]

77. Taniguchi, T.; Imoto, M.; Takeda, M.; Nakai, T.; Mihara, M.; Iwai, T.; Ito, T.; Mizuno, T.; Nomoto, A.; Ogawa, A. Hydrolysis of Diazonium Salts Using a Two-Phase System (CPME and Water). *Heteroat. Chem.* **2015**, *26*, 411–416. [CrossRef]

78. Duvvuru, B.; Amankulova, D.; Gauden, S.; Haffemayer, T.; Clive, D.L. A mild alternative to the classical Ullmann coupling for preparation of 3-aryloxy phenols. *Tetrahedron* **2023**, *133*, 133264. [CrossRef]